erenumab (aimovig) is the first of four new migraine drugs in the pipeline that target calcitonin gene-related peptide (cgrp), a molecule that's produced in nerve cells of the.
but shocking figures uncovered by labour yesterday show some patients are suffering agonising waits of as many as 541 days to begin treatment..